Interestingly, and in further support of FcγRIIB being a tractable target in cancer immunotherapy, recent data has demonstrated that this inhibitory antibody checkpoint limits therapeutic antibody efficacy and promotes antibody drug resistance by additional mechanisms distinct from inhibitory signaling in immune effector cells, when expressed on tumor B cells (65) (Figure 3). This evidence concerns the gene FCGR2B and cancer.